LONDON, July 9 (Reuters) - U.S.-based hedge fund Elliott Associates on Tuesday urged a London court to overturn a verdict supporting the London Metal Exchange's (LME) cancellation of nickel trades partly because the exchange failed to disclose documents. The LME annulled $12 billion in nickel trades in March 2022 when prices shot to records above $100,000 a metric ton in a few hours of chaotic trade. Elliott and market maker Jane Street Global Trading brought a case demanding a combined $472 million in compensation, alleging at a trial in June last year that the 146-year-old exchange had acted unlawfully. London's High Court ruled last November that the LME had the right to cancel the trades because of exceptional circumstances, and was not obligated to consult market players prior to its decision. Lawyers for Elliott told London's Court of Appeal that the LME belatedly released documents in May detailing its "Kill Switch" and "Trade Halt" internal procedures. It also newly disclosed an internal report that Elliott said detailed potential conflicts of interest at the exchange. "It was troubling that one gets disclosure out of the blue in the Court of Appeal for the first time," Elliott lawyer Monica Carss-Frisk told the court. Jane Street Global did not appeal the ruling. "If we had had them (documents) in the proceedings before the divisional court, we may well have sought permission to cross examine." LME lawyers said the new documents were not relevant. "The disclosed documents do not affect the reasoning of the divisional court or the merits of the arguments on appeal," the exchange said in documents prepared for the appeal hearing. "Elliott's appeal is largely a repetition of the arguments which were advanced, and rightly rejected." The LME said it had both the power and a duty to unwind the trades because a record $20 billion in margin calls could have led to at least seven clearing members defaulting, systemic risk and a potential "death spiral". Elliott said the ruling diluted protection provided by the Human Rights Act and also wrongly concluded the LME had the power to cancel the trades.

Recently, according to the FT, citing the latest forecast data of the market research institute SemiAnalysis, AI chip giant NVIDIA will ship more than 1 million new NVIDIA H20 acceleration chips to the Chinese market this year, and it is expected that the cost of each chip is between $12,000 and $13,000. This is expected to generate more than $12 billion in revenue for Nvidia. Affected by the United States export control policy, Nvidia's advanced AI chip exports to China have been restricted, H20 is Nvidia based on H100 specifically for the Chinese market to launch the three "castration version" GPU among the strongest performance, but its AI performance is only less than 15% of H100, some performance is even less than the domestic Ascend 910B. When Nvidia launched the new H20 in the spring of this year, there were reports that due to the large castration of H20 performance, coupled with the high price, Chinese customers' interest in buying is insufficient, and they will turn more to choose China's domestic AI chips. Then there are rumors that Nvidia has lowered the price of the H20 in order to improve its competitiveness. However, the latest news shows that due to supply issues caused by the low yield of the Ascend 910B chip, Chinese manufacturers in the absence of supply and other better options, Nvidia H20 has started to attract new purchases from Chinese tech giants such as Baidu, Alibaba, Tencent and Bytedance. Analysts at both Morgan Stanley and SemiAnalysis said the H20 chip is now being shipped in bulk and is popular with Chinese customers, despite its performance degradation compared to chips Nvidia sells in the United States.

From the perspective of the two major markets of the United States and China, the autonomous driving industry has fallen into a low tide in recent years. For example, last year, Cruise Origin, one of the twin stars of Silicon Valley autonomous driving companies and once valued at more than $30 billion, failed completely, its Robotaxi (driverless taxi) operation qualification was revoked, and autonomous driving models have been discontinued. However, as a new track with the deep integration of digital economy and real economy, automatic driving is a must answer: on the one hand, automatic driving will accelerate the process of technology commercialization and industrialization, and become an important part of the game of major powers; On the other hand, autonomous driving will also promote industrial transformation and upgrading by improving the mass travel service experience, seeking new engines for urban development, and injecting new vitality into the urban economy.

NEW DELHI, July 9 (Reuters) - India's beleaguered Paytm (PAYT.NS), opens new tab has secured approval from a government panel that oversees investments linked to China to invest 500 million rupees ($6 million) in a key subsidiary, three sources with direct knowledge of the matter said. The approval, which still has to be vetted by the finance ministry, will remove the main stumbling block to the unit, Paytm Payment Services, resuming normal business operations. Paytm Payment Services is one of the biggest remaining parts of the fintech firm's business, accounting for a quarter of consolidated revenue in the financial year ended March 2023. A separate unit, Paytm Payments Bank, was wound down this year by order of the central bank due to persistent compliance issues, triggering a meltdown in Paytm's stock. The government panel had earlier held back approval due to concerns about the 9.88% stake in Paytm held by China's Ant Group. India has intensified scrutiny of Chinese businesses since a 2020 border clash between the two countries. All in all, Paytm has been waiting for the nod from the government panel for about two years and without it, it would have had to also wind down its payment services business, which was forbidden from taking on new customers in March 2023. Once the approval has been formalised, it will be able to seek a so-called "payment aggregator" licence from the Reserve Bank of India. The sources, two of whom are government sources, declined to be identified as the decision has not been formally announced. India's foreign, home, finance and industries ministries, whose representatives sit on the panel, did not reply to emails seeking comment. A Paytm spokesperson said the company does not comment on market speculation. "We will continue to make disclosures in compliance with our obligations under the SEBI Regulations, and will inform the exchanges when there is any new material information to share," the spokesperson said.

White House spokeswoman Karina Jean-Pierre denied a report in the U.S. media on the 8th that President Joseph Biden did not receive treatment for Parkinson's disease. Biden had the first televised debate of the 2024 presidential election with Republican opponent Donald Trump on June 27, and his poor performance on the spot triggered discussions about his physical condition. The New York Times reported that a doctor specializing in the treatment of Parkinson's disease had "visited" the White House eight times from August last year to March this year. Facing the media's questions about Biden's health, Jean-Pierre asked and answered himself at a regular White House press conference on the 8th: "Has the president received treatment for Parkinson's disease? No. Is he currently receiving treatment for Parkinson's disease? No, he is not. Is he taking medication for Parkinson's disease? No." Jean-Pierre said Biden had seen a neurologist three times, all related to his annual physical examination. She also took out the report issued by the doctor after Biden's most recent physical examination in February this year. The report said, "An extremely detailed neurological examination was once again reassuring" because no symptoms consistent with stroke, multiple sclerosis or Parkinson's disease were found. The doctor who went to the White House mentioned by the New York Times is Kevin Kanal, a neurology and movement disorder expert at the Walter Reed National Military Medical Center in Maryland and an authority on Parkinson's disease. Jean-Pierre suggested that the doctor might have come to treat military personnel on duty at the White House.